ライフサイエンスコーパス: WHO classification

1 c test in meningioma and integrated into the WHO classification.

2 racy of risk of recurrence compared with the WHO classification.

3 assification systems, including the new 2022 WHO classification.

4 -group hierarchical scheme and the six-class WHO classification.

5 ing tumour recurrence and prognosis than the WHO classification.

6 ia and OGTT was interpreted according to the WHO classification.

7 an expert pathologic diagnosis according to WHO classification.

8 pathologists and classified according to the WHO classification.

9 Several new studies validate the WHO classification.

10 likely reflects changes in the revised 1999 WHO classification.

11 y (aHR = 1.43; 95% CI: 1.02, 2.00) using the WHO classification.

12 ountries into six world regions according to WHO classifications.

13 dated in the last World Health Organization (WHO) classification.

14 ions with the new World Health Organization (WHO) classification.

15 ption of the 2001 World Health Organization (WHO) classification.

16 according to the World Health Organization (WHO) classification.

17 oups by using the World Health Organization (WHO) classification (11).

18 cute myeloid leukaemia according to the 2016 WHO classification; an ECOG performance status of 0-2; a

19 papillary carcinomas in accordance with the WHO classification and because the identification of pap

20 cases of NHL from 5 CSA countries using the WHO classification and compared them to 400 cases from N

21 Diagnoses were confirmed according to WHO classification and graded as suggested by Jouvet et

22 r the first time, they considered the latest WHO classification and objective data in addition to exp

23 evance of entities currently included in the WHO classification and that also suggest new entities th

24 recurrent genetic abnormalities according to WHO classification and those with derivative chromosomes

25 ted risk score (MARS) was independent of the WHO classification and was confirmed in the independent

26 th edition of the World Health Organization (WHO) classification and the International Consensus Clas

27 xt of the current World Health Organization (WHO) classification and to evaluate the outcome of MK(+)

28 of Disease for Oncology (third edition) and WHO classification, and followed up to 2014.

29 were subcategorized according to the latest WHO classification, and tumor cellularity was calculated

30 ow that histologic criteria described in the WHO classification are difficult to apply reproducibly a

31 ised gliomas in the fifth edition of the CNS WHO classification, as well as other CNS tumor types com

32 lant is also critical, and predictive tools (WHO classification-based prognostic scoring system and h

33 morbidity index) and other predictive tools (WHO classification-based prognostic scoring system), and

34 ssue tumours, the World Health Organisation (WHO) classification categorises bone tumours based on th

35 The World Health Organisation (WHO) classification categorises musculoskeletal soft tis

36 patients with extranodal NKTCL, nasal type (WHO classification criteria; cases) and 957 controls fro

37 pite standardized World Health Organization (WHO) classification criteria, diagnostic concordance rem

38 Whereas the WHO classification defines its categories based on histo

39 e implication of rare tumour subtypes in the WHO classification for EACs according to the classificat

40 The WHO classification for well-differentiated pancreatic en

41 6 revision of the World Health Organization (WHO) classification for lymphoma has included a new cate

42 In 2008, the revised WHO classification has expanded this category into "AML

43 The WHO classification has produced a new and exciting degre

44 as a separate disease entity in the revised WHO classification has renewed efforts to improve the re

45 on adopted by the World Health Organization (WHO) classification has been validated in international

46 According to the WHO classification, Hodgkin's lymphoma (HL) is subdivide

47 Information was complete for the WHO classification in 1072 patients (85.5%) and for the

48 mphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the

49 The 4th edition of the WHO classification incorporates new information that has

50 The WHO classification is useful for defining subtypes of PT

51 will discuss the most recent updates to the WHO classification of bone tumours that are relevant to

52 The WHO classification of brain tumours describes 15 subtype

53 istics, they are classified according to the WHO classification of central nervous system (CNS) tumou

54 oups have broadly been incorporated into the WHO classification of central nervous system tumours but

55 g lesions classified as grade I or II by the WHO classification of CNS tumors.

56 Although the 2021 WHO classification of CNS tumours is a major conceptual

57 In the 2022 fifth edition of the WHO Classification of Endocrine Tumours and of Central N

58 e-control study of severe malaria, using the WHO classification of G6PD mutations to estimate each in

59 CL6, CXCL13, PD1, or ICOS) based on the 2017 WHO classification of haematological neoplasms, with an

60 logical classification of these lesions, the WHO classification of human tumors was used as a referen

61 inoma and BAC as newly published in the 2004 WHO Classification of Lung Tumors, and to address the pa

62 A major revision of the WHO classification of lymphoid and myeloid neoplasms and

63 this communication is to outline briefly the WHO classification of malignant myeloid diseases, to dra

64 In the current WHO classification of myeloid disorders, chronic neutrop

65 WHO classification of myeloid malignancies is based main

66 e been included in the current update of the WHO classification of myeloid neoplasms and AML, and mut

67 , yet unsolved diagnostic issues in the 2017 WHO classification of myeloid neoplasms and the importan

68 l Advisory Committee for the revision of the WHO Classification of Myeloid Neoplasms, who endorsed th

69 The recently updated WHO classification of pulmonary neuroendocrine neoplasms

70 C was published in the fourth edition of the WHO Classification of Skin Tumours Blue Book.

71 will discuss the most recent updates to the WHO classification of STT that are relevant to radiologi

72 new definition in the fourth edition of the WHO classification of the digestive tract tumors of 2010

73 ished explanation or rationale given for the WHO classification of the myeloid neoplasms.

74 ed follicular lymphoma-according to the 2008 WHO Classification of Tumors of Hematopoietic and Lympho

75 component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous Syst

76 blished a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Ly

77 The 2016 revision of the WHO Classification of Tumours of Haematopoietic and Lymp

78 with diffuse gliomas as defined in the 2021 WHO classification of tumours of the central nervous sys

79 The guideline is based on the 2016 WHO classification of tumours of the central nervous sys

80 The guideline is based on the 2016 WHO classification of tumours of the CNS and on scientif

81 A new edition of the WHO classification of tumours of the CNS was published i

82 uity (which was categorized according to the WHO classification of visual impairment and blindness},

83 alidated the 2001 World Health Organization (WHO) classification of acute myeloid leukemia (AML), inc

84 fined in the 2008 World Health Organization (WHO) classification of AML.

85 ighlighted by the World Health Organization (WHO) classification of central nervous system (CNS) tumo

86 e developed a new World Health Organization (WHO) classification of hematologic malignancies, includi

87 The World Health Organization (WHO) classification of hematolymphoid tumors and the Int

88 A World Health Organization (WHO) classification of hematopoietic and lymphoid neopla

89 The current World Health Organization (WHO) classification of hematopoietic malignancies define

90 ntity in the 2017 World Health Organization (WHO) classification of hematopoietic neoplasms.

91 ferences, the new World Health Organization (WHO) classification of lymphoma suggests further subdivi

92 eliability of the World Health Organization (WHO) classification of myelodysplastic syndromes (MDSs)

93 ntity in the 2017 World Health Organization (WHO) classification of myeloid neoplasms.

94 The World Health Organization (WHO) classification of myeloproliferative neoplasms (MPN

95 6 revision of the World Health Organization (WHO) classification of myeloproliferative neoplasms defi

96 th edition of the World Health Organization (WHO) classification of tumors of the central nervous sys

97 th edition of the World Health Organization (WHO) classification of tumors of the central nervous sys

98 The World Health Organization (WHO) classification of tumors of the hematopoietic and l

99 uldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on h

100 lved from the French-American-British to the WHO classification over the last few years.

101 We also wanted to determine if the WHO classification provided additional information about

102 The most recent WHO classification provides an updated classification sc

103 The most recent WHO classification provides an updated scheme that integ

104 Overall, the first published WHO classification, purely qualitative, lacked accuracy.

105 The revised 2008 WHO classification recognizes both molecularly defined (

106 s in the field, with emphasis on the updated WHO classification, refined criteria, additional prognos

107 The WHO classification reliably predicted therapeutic respon

108 This fact should be considered in future WHO classification reviews.

109 The DNA methylation-based and WHO classification schema were compared using the Brier

110 ial lesions and suggests that the simplified WHO classification scheme is appropriate for evaluation

111 In conclusion, in the 2008 WHO classification scheme, FAB subclassification does no

112 The WHO classification separates mastocytosis into distinct

113 microscopes, classifying slides based on the WHO classification standard of 100 fields of view (FoV)

114 trials (n = 309) with azacitidine using the WHO classification system for MDS and acute myeloid leuk

115 c disease characteristics in the most recent WHO classification system, improved understanding of the

116 cytic intraepithelial neoplasia, and 81% for WHO classification system.

117 three molecular groups according to the 2016 WHO classification system: (1) oligodendroglioma, IDH-mu

118 nct entity in the World Health Organization (WHO) classification system, is readily recognized as a p

119 agnosis using the World Health Organization (WHO) classification system.

120 Our data confirm the clinical impact of the WHO classification that separates ISM from CM and from o

121 The WHO classification, tumor stage, and grade were associat

122 nd mature per the World Health Organization (WHO) classification using CD1a and surface CD3 status.

123 The prognostic value of the WHO classification was confirmed in our study (p<0.0001)

124 Based on these results and to best fit the WHO classification, we grouped the patients into three g

125 f abnormal glucose tolerance between ADA and WHO classifications were significant (p<0.0001).